and death ). Compared to free treatment, fee for service programs were associated with no follow-up .05]) and higher mortality .41]).
Introduction
The increasingly widespread use since 1996 of potent antiretroviral combination therapy (ART) has substantially improved the prognosis of HIV-infected patients in industrialized countries. [1] [2] [3] In resource-constrained settings in Africa, Asia Using data from a network of treatment programs in Africa, Asia and Latin America, we examined early losses to program in individuals starting ART in low-income countries, including lack of follow-up after the initial visit and loss to follow-up and death in the first six months.
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Methods

Study population
The Antiretroviral Therapy in Lower Income Countries (ART-LINC) collaboration of the International Databases to Evaluate AIDS (IeDEA) (see www.art-linc.org and www.iedeahiv.org) is a network of HIV/AIDS treatment programs in Africa, South America, and Asia that has been described elsewhere. 5;6 In brief, treatment programs from low-and middleincome countries were approached to determine their interest and capacity to collaborate.
Programs that systematically collected prospective data on adolescents and adults aged 16 years or older starting ART were eligible; 23 treatment programs were approached, 19 agreed to participate and 15 contributed data to the present analysis. At all sites, institutional review boards or ethics committees approved the collection of data.
Information obtained on patients included age, sex, date of starting ART, type of treatment initiated, date of last contact with the program, date of death, and, when available, CD4 cell count, WHO clinical stage, total lymphocyte count, haemoglobin and HIV-1 RNA plasma level at baseline and during follow-up. The most common ART regimens were d4T/3TC/NVP, ZDV/3TC/EFZ, ZDV/3TC/NVP and d4T/3TC/EFZ. These four combinations accounted for 66% of all regimens used. 5 ; 6 Type of ART regimen was defined as protease inhibitor (PI)-based (2 nucleoside reverse transcriptase inhibitors (NRTIs) plus 1 PI, including ritonavir-boosted PI), non-nucleoside reverse transcriptase inhibitor (NNRTI)-based (2 NRTIs plus 1 NNRTI) and other combinations (including triple NRTI regimens and any other regimen containing a minimum of three drugs). The characteristics of treatment programs
were also recorded, including procedures in place for tracing patients lost to follow-up. We included all patients who had not previously received antiretroviral (ARV) drugs except for the prevention of mother-to-child transmission of HIV, were aged 16 years or older and had a documented date of starting ART.
5
Outcomes
We considered three endpoints to characterize losses to program: no follow-up, loss to follow-up and death in the first six months after starting ART. No follow-up refers to the situation when a patient never returned to the clinic after the ART initiation visit, although she or he had 12 months or more of potential follow-up until the closing date of the database. A patient was considered to be lost to follow-up if the last follow-up visit subsequent to ART initiation was recorded during the first six months after starting ART and the patient had at least another six months of additional potential follow-up until the closing date of the database. Loss to follow-up was assessed at six months to accommodate the longest interval between visits across programmes participating in the study. The closing date was defined as the date of the most recent follow-up visit in a given cohort.
Statistical analysis
Logistic regression with a random effect on cohort was used to examine factors associated with no follow-up. We used competing risk models 7 to analyse time to loss to follow-up and time to death, measuring time from the start of ART (baseline). Competing risk analysis assumes that each individual is exposed to two risks, loss to follow-up and death, and accounts for the fact that these risks may not be independent. The competing risk dataset was prepared by stacking of the data and generating separate strata for death and loss to follow-up, with each patients appearing in both strata. The effect of prognostic factors on outcomes was analyzed using a Weibull proportional hazard model, controlling for cohort and stratifying by event, thus allowing the baseline hazard to differ between competing risks. Robust variance adjustment was used to allow for the fact that each individual contributed two data points. Pvalues for the contribution of prognostic factors to the explained variance were derived by a Wald-test. The effect of program level factors was evaluated controlling for individual level factors. Overall 211 patients (3.8%) were not seen after the initial visit when ART was started, 880 (16.0%) were lost to follow-up later on and 141 (2.6%) were known to have died in the first six months, with considerable variation across treatment sites (Table 1) . Sites with larger numbers of patients were less likely to actively trace patients who did not return to the clinic, and these sites had also higher rates of loss to follow-up ( Figure 1 ).
Individual-level factors associated with the three outcomes are shown in Table 3 : more recent calendar years of starting ART were associated with an increased probability of loss to At the program level, as shown in Table 4 , being treated in a fee for service program was associated with increased probability of no follow-up and death. Furthermore, programs with no active tracing of patients in place were more likely to experience losses after the initial visit and less likely to record deaths. In programs with active follow-up, death rates are higher due to improved ascertainment of deaths.
Results from sensitivity analyses based on multiply imputed data for baseline CD4 cell count and clinical stage were similar to those presented here. Additional tables with these results are available from the authors on request. Of note, 81% of cases with unknown disease staging were classified as having advanced disease following multiple imputations, and in these analyses advanced stage was associated with no follow-up after the initial visit.
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Discussion
Summary of main findings
Using data from a large collaborative network of treatment programs in resourcelimited settings, we investigated three important early outcomes of ART: failure to return after the first prescription of ART, and loss to follow-up and death in the first six months after starting ART. We found that only 3% of patients were known to have died by six months, but on average 21% of patients had been lost to programs by that time, including about 4% who had not been seen since receiving their first prescription of ART. Losses to program increased substantially in more recent calendar periods compared to the period before the year 2000.
This suggests that many sites find it increasingly difficult to follow-up the growing population of patients, and to trace those not returning to the clinic. Confronted with the urgent, largescale need for treatment, starting a maximum number of new patients on ART has been the top priority of many public sector programs, with the possible consequence that infrastructure and number of staff for documenting and tracing of patients lost to follow-up has become increasingly inadequate.
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Strengths and limitations
An important strength of our study is the inclusion of a diverse group of clinics and programs, including sites that may not have reported their outcomes outside this collaborative network. This made the examination of factors that influence the probability of retention in programs both at the individual level and the level of program possible. However, we stress that the reasons for loss to follow-up were not collected systematically at the individual level.
Our study has several other limitations. While the ART-LINC cohorts are broadly representative of the types of ART services operating across resource-limited settings, the generalizability of these results requires careful consideration. A limitation of large 10 collaborative databases is the relatively small number of variables available for analysis: the standardization and harmonization of data collection across many different sites is challenging. This means that the available information is limited, which prevents examination of factors that are more difficult to assess, for example adherence.
Another limitation is that we were unable to explore the relationships between patient numbers, the approach to tracing patients, staffing and infrastructure with losses to program:
detailed, standardised and up-to-date information was not available and the size of treatment programmes was closely related to whether or not active tracing of patients was done. It was therefore not possible to unequivocally link time trends in loss to follow-up to changes in specific program characteristics over time. Program size and features of ART services that contribute to optimal patient outcomes require further investigation to inform decisions of national health systems and international donors on how to best deliver ART to large numbers of HIV-infected patients.
Results in context with other studies
We focussed on the first six months of treatment, which is a crucial period for the long-term success of ART. Initial response to ART is of long-term prognostic significance, and optimizing adherence in the early months of treatment is important to ensure long-term immunological and virological success. 9;10 Data from the ART-LINC collaboration 6 and other treatment programs, for example the Médecins Sans Frontières (MSF) program in Malawi, showed that loss to follow-up and death mostly occur in the first six months after ART initiation and that community support improved outcomes. 11;12 Not all studies have shown this, however. Data from a South African ART program demonstrated that while mortality decreased rapidly after ART initiation, rates of loss to follow-up remained fairly constant during the first two years on ART. 13 
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Other studies of treatment programs in resource-limited settings also found high rates of loss to follow-up. Other studies found lower rates of loss to follow-up: in Port-au-Prince, Haiti, for example, only 71 (7%) of 910 patients were lost over a median 13 months of follow-up. 16 In a large observational cohort of Médecins sans Frontières (MSF) HIV/AIDS programs 4.8% of patients were lost to follow-up over a median period of 4.1 months. 17 Unfortunately, the results from studies are often not directly comparable because definitions of loss to follow-up differed, or because no clear definition was reported. Of note, whether a patient is lost to follow-up can only be determined retrospectively, and only for patients who potentially could have been seen at the clinic before the data were analysed. Some cohorts were established in a clinical research context, with relatively small numbers of patients who were closely monitored. [18] [19] [20] [21] These studies reported low rates of loss to follow-up, but they will not reflect the realities and constraints many clinics and programs face in the context of scaling up ART.
Reasons for losses to follow-up
Few programs in resource-limited settings systematically assess the reasons for losses to follow-up, but surveys found that a substantial proportion of those lost had died. For example, among 727 patients lost to follow-up at the Lighthouse clinic in Lilongwe, Malawi, 30% had died, 19% transferred to another facility, 22% were alive and on treatment, 3% had stopped treatment and 26% could not be found. The latter group had a low median CD4 count, suggesting that some of these patients may also have died. 22 A smaller study from northern Malawi investigated the fate of 253 patients lost to follow-up and reported that 50% 12 had died, 23% were alive and 27% could not be traced, mainly because the address was incorrect. 23 Similarly, among 801 patients traced after they missed scheduled visits in Lusaka, Zambia, 46% had died. 24 Taken together, these data suggest that about 50% of patients lost to follow-up in lower-income settings may have died.
The present analysis extends our previous study of mortality in high-income and lowincome countries 6 and shows that free access to treatment is a critical determinant of program retention, as well as mortality. This association was particularly strong with no follow-up after ART was started, whereas there was little evidence for an association with loss to follow-up later on. Interestingly, in the UNAIDS/Uganda Ministry of Health HIV Drug Access Initiative, a fee for service program, the majority of patients (65%) who were lost did not return after their initial visit. 15 As discussed previously, 6 payments for ARVs during the initial treatment phase do not mean that households have the ability to pay later on. Provision of ART free of charge was also found to be associated with an increased probability of achieving and maintaining suppression of viral replication, and better adherence to therapy. 25 At the individual level, we found that older age and profound immune suppression are associated with early losses. One might speculate that some older people fail to return to the clinic because they do not want to be a burden to their families, who may contribute to the costs of care and transport. Patients with advanced HIV infection may not return because they are too weak to travel. Access to transport is also important in this context. For example, ownership of a bicycle was associated with reduced loss to follow-up in one program, but patients' access to individual or public transport was not consistently assessed across programs and sites. In the Lusaka program, some patients had stopped treatment because of high transport cost. 23 In the large Academic Model for the Prevention and Treatment of HIV/AIDS (AMPATH) program in Eldoret, Kenya, men were more likely to be lost to 13 follow-up than women. 26 In our study there was some evidence that men were less likely than women to return to the clinical after the initial visit.
Implications and conclusions
Our results support the notion that evaluations of the scale-up of ART in resourcelimited settings should consider not only the numbers of new patients starting ART but also the number remaining in care long-term: loss to follow-up is an important indicator of programme effectiveness. 13 Our results indicate that better ART outcomes (including higher retention in programs) may be obtained in services that have smaller numbers of patients, compared to larger services, and that therefore population coverage should be achieved with smaller, decentralized facilities rather than few large programs. In general, given the large numbers of patients and limited resources facing health services, the development of strategies that prevent patients from missing appointments may be more efficient than spending resources on tracking those not returning to the clinic. 8 Future studies should address the causes of late initiation of ART 13 as well as the barriers preventing some patients from returning to clinics, and record transfers to other programs and assess mortality in patients lost to programs. In conclusion, early losses to ART programs are increasingly common in resource-limited countries. This should not detract from the fact that many patients benefit from the introduction and scaling-up of ART in these settings or from the need for continued efforts to improve access to therapy.
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